SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

NBIS is trending due to a recently announced $17.4B deal with Microsoft for AI infrastructure, leading to comparisons with other AI infrastructure plays like CRWV. Community members are speculating about future deals with other major tech companies and the potential for a short squeeze. Some investors believe this is just the beginning for NBIS as it gains recognition as a key player in the AI cloud space.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings is trending due to a recent public offering of 40 million shares at $5.00, sparking concerns about dilution among investors, while others view the $200M capital raise as a bullish move for strategic growth and potential acquisitions. The community is actively debating the implications of the offering, with some expressing frustration and others seeing it as a necessary step for the company's expansion in the drone technology sector.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as the community anticipates potential ETF approval and discusses the recent accumulation of DOGE by institutions, including CleanCore's treasury initiative. Bullish sentiment is fueled by technical indicators and the possibility of increased adoption, while some traders are wary of potential pullbacks. The conversation also includes comparisons to other meme coins and the potential impact of Elon Musk's X platform on Dogecoin's utility.

American Bitcoin Corp. is a bitcoin accumulation platform focused on building America's bitcoin infrastructure platform. It delivers institutional-grade exposure to bitcoin through an industry-first business model that integrates scaled self-mining operations with disciplined accumulation strategies. The company was founded on October 22, 2020 and is headquartered in Miami, FL.

American Bitcoin Corp. - Ordinary Shares - Class A

American Bitcoin Corp.

American Bitcoin Corp. ($ABTC) is trending amid high volatility following its NASDAQ debut, driven by excitement and skepticism around its ties to the Trump family and its positioning as a Bitcoin mining play. The community is actively debating the company's valuation, potential for a short squeeze, and the impact of a recent offering.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

Albemarle Corp. engages in the development, manufacture, and marketing of chemicals for consumer electronics, petroleum refining, utilities, packaging, construction, transportation, pharmaceuticals, crop production, food-safety, and custom chemistry services. It operates through the following segments: Energy Storage, Specialties, Ketjen, and All Other. The Energy Storage segment develops and manufactures a broad range of basic lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride. The Specialties segment focuses on optimizing a portfolio of bromine and specialized lithium solutions. The Ketjen segment consists of clean fuels technologies, fluidized catalytic cracking catalysts and additives, and performance catalyst solutions, which is primarily composed of organometallics and curatives. The All Other segment refers only to the FCS business that did not fit into any of the company’s core businesses. The company was founded in 1993 and is headquartered in Charlotte, NC.

Albemarle Corp.

Albemarle Corp

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

Anavex Life Sciences Corp

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Down 21.7% in 4 Weeks, Here's Why Soleno Therapeutics (SLNO) Looks Ripe for a Turnaround 

The heavy selling pressure might have exhausted for Soleno Therapeutics (SLNO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Shares of Soleno Therapeutics (SLNO) slumped 7% on Friday afternoon after Scorpion Capital revealed a short position on the stock, citing risks associated with the company’s drug approved for Prader-Willi syndrome.The shortseller alleged several risks associated with Vykat XR, including high risk of pre-diabetes/diabetes, pulmonary edema, and congestive heart failure. It further alleged that the drug may be at risk of being withdrawn from the market, or new prescriptions may plunge.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SLNO">Soleno</a> trended in the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:1366/124;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_15_at_12_42_29_PM_png_0f8718e0b7.webp" alt="SLNO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on Aug. 15, 2025 | Source: Stocktwits" width="1366" height="124"><figcaption>SLNO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on Aug. 15, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user dismissed the short seller report, citing inconsistencies with public data.<stembedurl>https://stocktwits.com/aristocks/message/625341208</stembedurl>Another believes the stock is a good buy-the-dip candidate.<stembedurl>https://stocktwits.com/CrispDry/message/625323181</stembedurl>Scorpion Capital said in its report that Soleno is reminiscent of the company Zafgen, which announced two patient deaths in 2015 during a trial with an investigational Prader-Willi syndrome drug, leading to discontinuation of the program. Zafgen subsequently merged with Larimar Therapeutics in 2020.“SLNO is at high risk of fading back into obscurity as a zombie biotech that trades near cash - $9/share - round-tripping back to single-digit or penny stock status, as it was a mere ~2.5 years ago when it hit 90 cents,” Scorpion Capital <a target="_blank" rel="noopener noreferrer nofollow" href="https://scorpionreports.s3.us-east-2.amazonaws.com/SLNO1.pdf">said</a> in its report. The firm further alleged that Soleno has “no meaningful assets, pipeline or scientific program, and its only drug is an inferior tablet version of a half-century-old suspension.”Scorpion Capital also stated that it intends to shortly submit an emergency Citizen Petition asking the FDA to request Soleno to conduct a voluntary recall of VYKAT XR from the market.Soleno <a href="https://stocktwits.com/news-articles/markets/equity/soleno-therapeutics-gets-fda-approval-for-prader-willi-syndrome-drug/chJ25DRRbE3">received</a> the U.S. Food and Drug Administration’s approval for Vykat XR extended-release tablets for the treatment of hyperphagia in patients four years of age and older with Prader-Willi syndrome in March and subsequently launched it in April. VYKAT XR is the company’s first commercial product.Prader-Willi syndrome is a rare genetic neurodevelopmental disorder caused by an abnormality in the gene expression on chromosome 15, estimated to occur in one in every 15,000 live births. The disorder is defined by hyperphagia, an intense, persistent sensation of hunger, which could be life-threatening.Scorpion Capital has previously revealed short positions in multiple pharmaceutical and biotechnology companies, including Transmedics Group Inc (TMDX), Harmony Biosciences (HRMY), Twist Bioscience (TWST), and more.SLNO stock is up by 60% this year and by about 42% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/cleveland-cliffs-enters-multi-year-steel-deals-with-automakers-report/chsPDjERdfH">Cleveland-Cliffs Enters Multi-Year Steel Deals With Automakers, Says Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Soleno Therapeutics Stock Slumps After Scorpion Capital Reveals Short Position: But Retail’s Not Pessimistic Yet

The shortseller alleged several risks associated with Vykat XR, including high risk of pre-diabetes/diabetes, pulmonary edema, and congestive heart failure.

Equity

How Much Upside is Left in Soleno Therapeutics (SLNO)? Wall Street Analysts Think 43.15%

The average of price targets set by Wall Street analysts indicates a potential upside of 43.2% in Soleno Therapeutics (SLNO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Here's Why Momentum in Soleno Therapeutics (SLNO) Should Keep going

Soleno Therapeutics (SLNO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Soleno Therapeutics, Inc. (SLNO) Reports Q2 Loss, Tops Revenue Estimates

Soleno Therapeutics (SLNO) delivered earnings and revenue surprises of +83.02% and +1.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Soleno Therapeutics, Inc. (SLNO) is a Great Momentum Stock: Should You Buy?

Does Soleno Therapeutics, Inc. (SLNO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Can Soleno Therapeutics (SLNO) Climb 33.11% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for Soleno Therapeutics (SLNO) points to a 33.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Here's What Could Help Soleno Therapeutics (SLNO) Maintain Its Recent Price Strength

If you are looking for stocks that are well positioned to maintain their recent uptrend, Soleno Therapeutics (SLNO) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Shares of biopharmaceutical company Soleno Therapeutics, Inc. (SLNO) were in the spotlight on Monday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.soleno.life/news-releases/news-release-details/soleno-therapeutics-announces-vykattm-xr-launch">announced</a> the launch of its VYKAT XR extended-release tablets in the U.S. as a treatment for hyperphagia in patients four years of age and older with Prader-Willi syndrome (PWS).VYKAT XR has now been delivered to the first individuals living with PWS who have been prescribed the medication, the company said.Prader-Willi syndrome is a rare genetic neurodevelopmental disorder caused by an abnormality in the gene expression on chromosome 15, estimated to occur in one in every 15,000 live births.The disorder is defined by hyperphagia, an intense, persistent sensation of hunger, which could be life-threatening.Soleno Therapeutics CEO Anish Bhatnagar said that the drug saw “strong interest” following approval from the U.S. Food and Drug Administration (FDA) in late March.“Our team is fully prepared to meet demand and is well-positioned to execute a successful commercial launch of this first-to-market treatment.”VYKAT XR is the company’s first commercial product. The pills have to be consumed orally once a day.Soleno said the common adverse effects identified in 10% or more individuals receiving the drug include hypertrichosis, edema, hyperglycemia, and rash.On Stocktwits, retail sentiment around Soleno stayed unmoved within ‘bearish’ territory over the past 24 hours, coupled with ‘extremely low’ message volume.<figure class="image"><img style="aspect-ratio:647/150;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_14_at_9_00_06_AM_png_f6762d4e34.webp" alt="SLNO's Sentiment Meter and Message Volume as of 9:00 a.m. ET on April 14, 2025 | Source: Stocktwits" width="647" height="150"><figcaption>SLNO's Sentiment Meter and Message Volume as of 9:00 a.m. ET on April 14, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/SLNO">SLNO stock</a> is up by over 45% year-to-date and by over 72% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/third-harmonic-bio-devises-plan-to-dissolve-company/chfCdnIRba5">Third Harmonic Bio Announces Liquidation Plan: Stock Skyrockets 39% Pre-Market, But Retail’s Shattered</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

Soleno Launches Pill For Hyperphagia In Prader-Willi Syndrome Patients But Retail’s Unmoved

VYKAT XR has now been delivered to the first individuals living with PWS who have been prescribed the medication, the company said.

Shares of Soleno Therapeutics (SLNO) rocketed nearly 34% in premarket trading on Thursday after the biopharmaceutical company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.soleno.life/news-releases/news-release-details/soleno-therapeutics-announces-us-fda-approval-vykattm-xr-treat">received</a> approval from the Food and Drug Administration (FDA) for its VYKAT XR extended-release tablets.If the pre-market gains are sustained, the stock is headed toward its eight-year highs on a closing basis.In adults, VYKAT XR tablets are used to treat hyperphagia, an intense, persistent sensation of hunger. They are also used to treat children of the age of four or above with Prader-Willi syndrome, a rare genetic neurodevelopmental disorder caused by an abnormality in the gene expression on chromosome 15.PWS is estimated to occur in one in every 15,000 live births.The company expects the drug, the first approved therapy to address hyperphagia in PWS patients, to be available in the U.S. starting April 2025. The tablets have to be consumed orally once every day.CEO Anish Bhatnagar said the approval of VYKAT XR is a significant milestone for Soleno and, most importantly, for the PWS community, who have had no options to treat the most disruptive aspect of this disease.VYKAT XR is the company’s first commercial product.Soleno said the common adverse effects identified in 10% or more individuals receiving the drug include hypertrichosis, edema, hyperglycemia, and rash.On Stocktwits, retail investor sentiment about Soleno jumped further into the ‘extremely bullish’ territory (100/100) accompanied by significant retail chatter over the past 24 hours.<figure class="image"><img style="aspect-ratio:649/149;" src="https://news.stocktwits-cdn.com/Screenshot_2025_03_27_at_7_52_39_AM_png_aa2d4ebc9e.webp" alt="SLNO's Sentiment Meter and Message Volume as of 7:50 a.m. ET on March 27, 2025 | Source: Stocktwits" width="649" height="149"><figcaption>SLNO's Sentiment Meter and Message Volume as of 7:50 a.m. ET on March 27, 2025 | Source: Stocktwits</figcaption></figure>Stocktwits user comments indicated a positive take on the shares.<stembedurl>https://stocktwits.com/Royalty_Ba/message/609389592</stembedurl><stembedurl>https://stocktwits.com/MontanaT/message/609389586</stembedurl><a href="https://stocktwits.com/symbol/SLNO">Soleno shares</a> gained nearly 7% in 2025 and by over 14% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tsla-stock-faces-more-pressure-from-trump-auto-tariffs/chJcUDRRbE2">Tesla Stock Faces More Pressure As Musk Says Trump Tariffs Will Have An Impact, Retail Clings To Bullish Hopes</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market data with uptrend vector | Illustration Source: Getty Images

Soleno Therapeutics Stock Rockets 34% Pre-Market After FDA Approves Prader-Willi Syndrome Drug: Retail Sentiment Peaks 

The company expects the drug, the first approved therapy to address hyperphagia in PWS patients, to be available in the U.S. starting April 2025.

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	$0.05	--	--	N/A
Q2 '25	-$0.45	-$0.09	80.15%	BEAT
Q1 '25	-$0.97	-$0.95	2.06%	BEAT
Q4 '24	-$0.97	-$1.27	-30.42%	MISSED
Q3 '24	-$0.61	-$1.83	-202.48%	MISSED

SLNO
Soleno Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest SLNO News

SLNO Soleno Therapeutics Inc